Trial reportAntimicrobial agents and chemotherapy2021
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
Open access · greenAbstract readClinical Trial, Phase IVMulticenter Study
In one paragraph
Trial report in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation.Frontiers in pediatrics · 2026Article
- High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision.Infectious diseases and therapy · 2026Article
- Changing Genotypes andInfection & chemotherapy · 2025Article
- Establishing Clinical and Laboratory Standards Institute M45 antimicrobial susceptibility testing methods and breakpoints forJournal of clinical microbiology · 2025Article
- Review
- Defining antimicrobial susceptibility testing methods and breakpoints amongJournal of clinical microbiology · 2025Article
- Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.The Journal of antimicrobial chemotherapy · 2025Article
- The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-ResistantMicroorganisms · 2025Review
- Minocycline Susceptibility of Carbapenem-ResistantInfection & chemotherapy · 2025Article
- Review
- The challenges of difficult-to-treatClinical microbiology reviews · 2024Review
- Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.The Journal of antimicrobial chemotherapy · 2024Article
- Optimizing Antibiotic Therapy forAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 15 institutions in 1 country.
Thomas P LodiseAlbany College of Pharmacy and Health Sciences, Albany, New York, USA Thomas.Lodise@acphs.edu.ORCID 0000-0002-4730-0655
Scott Van WartEnhanced Pharmacodynamics, LLC, Buffalo, New York, USA.
Zoe M SundDuke University, Durham, North Carolina, USA.
Adam M BresslerInfectious Disease Specialists of Atlanta, Decatur, Georgia, USA.
Akram KhanOregon Health and Science University, Portland, Oregon, USA.
Amy T MakleyDepartment of Surgery, University of Cincinnati, Cincinnati, Ohio, USA.
Yasir HamadDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-6616-7127
Robert A SalataDivision of Infectious Diseases and HIV Medicine, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Fernanda P SilveiraDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Matthew D SimsBeaumont Hospital, Royal Oak, Michigan, USA.
Badih A KabchiBrody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
Mohamed A SaadUniversity of Louisville, Louisville, Kentucky, USA.
Carrie BrownEmmes, Rockville, Maryland, USA.
Randolph E OlerEmmes, Rockville, Maryland, USA.
Vance FowlerDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
Richard G WunderinkNorthwestern University, Chicago, Illinois, USA.
Emmes (United States) · USAlbany College of Pharmacy and Health Sciences · USAngioDynamics (United States) · USBeaumont Hospital, Royal Oak · USDuke Medical Center · USDuke University · USEast Carolina University · USGeorgia Cancer Specialists · USNorthwestern University · USOregon Health & Science University · USUniversity Hospitals of Cleveland · USUniversity of Cincinnati · USUniversity of Louisville · USUniversity of Pittsburgh Medical Center · USWashington University in St. Louis · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MTechnology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUIS A. Nunes AMARAL · 2018 to 2026
$24.7MMentoring Patient Oriented Research in Antibiotic-Resistant BacteriaK24AI093969 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G. · 2011 to 2020
$1.6MNIAID NIH HHS K24 AI093969NIAID NIH HHS U19 AI135964NIAID NIH HHS UM1 AI104681
Abstract
Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR)
Indexed as
Acinetobacter baumanniiMinocyclineAdultAnimalsAnti-Bacterial AgentsCritical IllnessHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsMinocyclineAcinetobacterminocyclinepharmacodynamicspharmacokineticspopulation pharmacokinetics
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.